Lv4
450 积分 2025-09-24 加入
Delisting regulation and corporate financialization: Evidence from China
14天前
已完结
[Expert consensus on the multidisciplinary integrated management of atopic dermatitis and its comorbidities(version 2026)]
1个月前
已完结
Zanidatamab With or Without Tislelizumab Yields Clinically Meaningful Survival Benefit in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
1个月前
已关闭
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
1个月前
已完结
RRAS and RRAS2 Mutations Are Recurrent Oncogenic Drivers in Lung Cancer and Are Sensitive to the Pan-RAS Inhibitor RMC-6236
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
3个月前
已完结
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics
3个月前
已完结
IgA Nephropathy in Adults
3个月前
已完结
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
3个月前
已完结
皖公网安备34019202002308
